A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
about
The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeEvaluation and Management of Neurogenic Bladder: What Is New in China?Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladderTreatment Options for Urogenital Dysfunction in Parkinson's DiseaseMirabegron in overactive bladder patients: efficacy review and update on drug safetyThe analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression.The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsCUA guideline on adult overactive bladderCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladderCost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United KingdomPostmenopausal overactive bladderThe efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectivesMirabegron: a Beta-3 agonist for overactive bladder.Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.Overactive bladder - 18 years - Part IIMirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Profile of mirabegron in the treatment of overactive bladder: place in therapy.Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelinesCritical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Mirabegron in the treatment of overactive bladder.Latest pharmacotherapy options for benign prostatic hyperplasia.Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.Urinary incontinence in men: current and developing therapy options.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.A drug safety evaluation of mirabegron in the management of overactive bladder.Current and future pharmacotherapy for treating overactive bladder.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Treatment of Concomitant OAB and BPH.
P2860
Q26770419-AA2026CE-257A-4EC8-8529-A582D158E388Q26783536-92D98101-3268-4A73-8315-BBB23312A693Q26798495-D1671D06-6D77-4829-A76D-A84325F78712Q27497430-64C344CB-21CE-44C3-9034-BD060BA41E31Q28072055-6F4434E9-BE93-4D17-85C4-AD20EDA0A98DQ28072230-CF4FCBAC-2E7E-4514-8CAD-4BAFE0F0993EQ30880978-247DC8F2-1602-4D42-A50A-46CAC8664FD3Q30894093-41AE539F-1BC6-47AF-A499-6C856D36523EQ33665026-6CB3A94D-A6EA-4A2B-96C4-7B5E0DA58139Q33696642-C4C99F73-5AF0-4EE3-815A-0CEE30CD1EF9Q33727733-E0C871DB-B795-40E6-9463-21EB64801C9BQ34405906-DE590817-115A-455E-8C7D-A47D0A4146B9Q34538448-3D4DD60C-21E9-4830-BE8D-63954AD80CA5Q34990256-1D4BABA7-D3FC-413F-97B3-F9647EA978F0Q35157329-019FE80B-D2B9-41BE-82B2-C77067D59F51Q36086072-CDFA0F1C-2ED6-48BA-A882-67EBB43BBB32Q36133212-6FA26301-506A-42C7-8C8A-2229061E07B0Q36160960-AF9FF0A8-662D-4785-89A4-135C1CB10BADQ36625281-20C101B0-13E9-4A2B-9381-10CFFF1D0D2CQ36912766-D98E5C4C-361D-4FEB-8C89-96829581B881Q37119868-85254DCF-7F50-46A8-A338-C9F3BCABB907Q37390990-EB3C813F-C3D1-4551-AAD3-67D6B8BAA8C0Q37664787-DFA697F7-EB98-494D-9443-5B359689F3C1Q37720749-4A611DA3-E95F-4C20-BA22-B22910189BA5Q38193896-CA44D17C-5BDC-44C6-80BE-D6424F216EA7Q38197276-103900CB-C4B1-4425-B2B2-BDE85ED57F14Q38244053-7426233C-9F91-4FD8-A7CB-D90739B3D2ACQ38570412-3C2D1BB1-B9F7-42E6-9746-119B0DD2C230Q38577301-352EE6C5-54C3-4DB4-966B-CBD45808AD46Q38626236-D3DF62F7-EA8C-47E9-8871-7CB007299EFCQ38649685-E8A35915-11A8-419C-ADDC-E8678AB2F703Q38708104-AACDB962-58A1-4EC5-B813-18AC42B31F33Q38765381-5D154CE2-B762-4B96-B083-F08B0AB6ADF5Q38776115-7AA24E73-F782-4BF4-85A7-D3CF4F2FD66FQ38851523-4D87191D-2B1F-4947-9318-1904EECB3FBFQ38911819-6488436B-7C2A-4C90-8A0C-E2C43B66D4EBQ38993756-81C4F920-43D4-497D-BB1B-FF618252D976Q39020998-7BBC5AF9-997D-4B34-A323-8D8987EFB24BQ39046374-8C111FE6-10C3-48F0-ABC7-6349D264D6C1Q39090324-3FF416F6-35A8-42C3-97D3-E23CF0ADF3AA
P2860
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@en
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@nl
type
label
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@en
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@nl
prefLabel
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@en
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@nl
P2093
P1433
P1476
A phase III, randomized, doubl ...... ymptoms of overactive bladder.
@en
P2093
Adrie Gunther
Angelo E Gousse
David Castro-Diaz
Jack Barkin
Jeffrey M Frankel
Matthias Stölzel
Montserrat Espuna-Pons
Nancy Martin
Philip Van Kerrebroeck
Sender Herschorn
P304
P356
10.1016/J.UROLOGY.2013.02.077
P407
P577
2013-06-13T00:00:00Z